NewsMunchies

DECEMBER 13, 2021

In the largest clinical trial to date, a new study conducted by the UK-based pharmaceutical company Compass Pathways shows that psilocybin or “magic” mushrooms can safely relieve depression. The trial included 233 patients from 10 countries in North America and Europe. In 2019, Denver became the first city in the U.S.

Clinical Trials 95

Clinical Trials Therapy Decriminalization Patients 95

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. tumor necrosis factor receptor I (TNFRI) and IL-6.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? There are many different medical cannabis products. .

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Cannigma

FEBRUARY 1, 2023

Advocate for the rescheduling of cannabis to improve access to cannabis for research purposes, and scientific funding for novel cannabinoid-based cancer therapies. To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer. Use harm reduction techniques (i.e.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

The Cannigma

JUNE 14, 2021

‘Junk’ cannabis ‘ill-suited for clinical trials’. The cannabis grown at the University of Mississippi “is junk, ill-suited for clinical trials, and genetically closer to hemp than the marijuana available from dispensaries and used by Americans nationwide,” according to the lawsuit. Shutterstock).

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Veriheal

JUNE 29, 2021

In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. The FDA refers to this program as the expanded access program on their website. A Push by Patients. Patients Are Not In This Alone.

Therapy 64

Therapy DEA Patients Clinical Trials 64

Cannabis Law Report

JULY 28, 2021

This includes First Time in Human (“FTiH”) clinical trials, which are expected to commence in 2022, for the Group’s lead compound OCT461201, a selective cannabinoid receptor type 2 (“CB2”) agonist with initial indications in the areas of post herpetic neuralgia and visceral pain caused by irritable bowel syndrome.

Cannabinoids 105

Cannabinoids Clinical Trials Safety Medicine 105

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. European Regulatory Lead Executive Summary.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Accessed July 25, 2021. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

OCTOBER 2, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. We are pioneering a new kind of pharmaceutical company that prioritizes public benefit and is committed to sustainability, accountability, and transparency.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

NewsMunchies

NOVEMBER 12, 2021

Psilocybin is the active ingredient found in magic mushrooms and research suggests it has the potential to treat various mental illnesses and is safer than pharmaceutical drugs and alcohol, which can be habit-forming. Additional clinical trials underway in the U.S. and Europe are aimed at winning regulatory approval.

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

Cannabis Law Report

NOVEMBER 7, 2021

The committee has been formed to expand the company’s pharmaceutical expertise and accelerate R&D, product development and clinical trials ahead of a potential NASDAQ listing. The committee will also enable CPH to accelerate R&D, product development and other clinical trials ahead of its potential NASDAQ listing.

Medicine 52

Medicine Clinical Trials Research and Development Pharmaceutical 52

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. CBD Oil for Medical Conditions CBD oil has gained popularity as a versatile and accessible option for managing various medical conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

FEBRUARY 5, 2022

5+ years’ experience in pharmaceutical industry preferably prescription medicines, narcotics, experimental drugs or products supplied via access schemes. Experience with prescription drug registration submissions and lifecycle management, including clinical trial activities. Experience in project management.

Medicine 52

Medicine Research and Development Clinical Trials Pharmaceutical 52

Cannabis Law Report

DECEMBER 15, 2021

5+ years’ experience in pharmaceutical industry preferably prescription medicines, narcotics, experimental drugs or products supplied via access schemes. Experience with prescription drug registration submissions and lifecycle management, including clinical trial activities. Experience in project management.

Medicine 52

Medicine Research and Development Clinical Trials Pharmaceutical 52

The Cannigma

APRIL 12, 2023

Cannabis is often reported to help people reduce the number of pharmaceuticals they’re taking, and this trend continues in this study. Sleep is not often the focus of clinical trials on cannabis; rather it is often a secondary outcome. Has CBN been proven to help with sleep? This CBN study is one such example.

Sleep 135

Sleep Data Tincture Research and Development 135

MGC Pharma

FEBRUARY 20, 2018

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon. Notably, 41% of the Cannabis users stopped using opioids altogether.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Cannabis Law Report

SEPTEMBER 1, 2021

The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. Doug Drysdale is an experienced director, having been CEO and chairman of the board of Nasdaq-listed companies and pharmaceutical firms.

Research and Development 102

Research and Development Therapy Clinical Trials Pharmaceutical 102

Cannabis Law Report

JUNE 21, 2021

Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. But if that doctor has access to information from 40,000 patients it’s a different story.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

APRIL 21, 2022

Commercialization & Patient Access · Any City, Any State, California. It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine and profiled on the front page of The New York Times. About MAPS Public Benefit Corporation (MAPS PBC).

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

Cannabis Law Report

JANUARY 11, 2022

In a recent peer-reviewed study conducted independently by Colorado State University researchers and published in the open-access scientific journal Pharmaceuticals , it was found that Ripple products absorbed into the bloodstream significantly faster (Ripple Gummies 2.3X faster), and Ripple Dissolvables (1.9X

THC 52

THC Clinical Trials Research and Development Sleep 52

Cannabis Law Report

DECEMBER 18, 2019

…MGC Pharmaceuticals has achieved yet another significant milestone with the bio-pharma company this week surpassing more than 1,800 prescribed products of its medicinal cannabis-based pharmaceutical products in Australia, UK, Brazil and Ireland. The West Australian reports. Source: [link].

Research and Development 59

Research and Development Clinical Trials Seed-To-Sale Pharmaceutical 59

Cannabis Law Report

FEBRUARY 3, 2022

With its newly licensed factory, MediCane intends to increase the access of this growing patient population to high quality medical cannabis sourced from its own organic cultivation, as well as from other reputable local and global cultivators. ”

Clinical Trials 52

Clinical Trials Research and Development Packaging Oil 52

Cannabis Law Report

OCTOBER 10, 2021

Cantourage is an innovative company ensuring that patients are able to access the newest medicinal products based on cannabis. As a senior manager at Cantourage and with us as a team you can develop and shape the pharmaceuticals market in Europe.

Clinical Trials 52

Clinical Trials Therapy Medicine Pharmaceutical 52

The Joint Blog

JUNE 2, 2020

The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. Participants inhaled a precise dose containing either THC (at doses of either 0.5mg or 1mg) or placebo.

Chronic Pain 58

Chronic Pain Clinical Trials Safety Marijuana 58

Veriheal

MARCH 23, 2023

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. Japan’s latest Cannabis Control Law revisions would apply to pharmaceutical-grade medicinal cannabis products.

Legalization 81

Legalization Marijuana Clinical Trials Seed-To-Sale 81

Project CBD

MAY 3, 2023

Remember, the pharmaceutical model is “this medicine addresses this specific target.” There are pharmaceuticals for ADHD or behavioral issues, for example, which target this receptor. Dr. Goldstein: We don’t have clinical trials to say, yes this is definitively beneficial or detrimental for children.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. Deputy General Counsel Executive Summary.

Therapy 40

Therapy Compliance Compliance Clinical Trials 40

Cannabis Law Report

JULY 1, 2021

Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. Access to Psychedelic Therapies and Equity in Emerging Psychedelics Industries. Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. Background.

Law 59

Law Policy Research and Development Clinical Trials 59

Peninsula Alternative Health

MAY 15, 2019

Unfortunately, the conventional pharmaceuticals used to treat these symptoms have significant side effects leaving families with no solution. Some of the common symptoms associated with autism are tics, depression, restlessness, and rage attacks. These symptoms can be unbearable for both patients and their caregivers. References Staff, T.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Cannabis Law Report

FEBRUARY 9, 2022

The application includes claims that Vocan’s technology will enable the production of cGMP API grade psilocybin, which can be used by pharmaceutical companies, API manufacturers and organizations conducting clinical trials and, where permitted by law, consumers, and patients.

Research and Development 52

Research and Development Clinical Trials Treatment Patients 52

Cannabis Law Report

NOVEMBER 16, 2019

Current barriers to patient access to medicinal cannabis in Australia. On 14 November 2019, the Senate referred an inquiry into the current barriers to patient access to medicinal cannabis in Australia to the Senate Community Affairs References Committee for inquiry and report by 12 February 2020. Accessibility.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58